Clinical Study on Tanggankang Capsule in Treatment of 30 Cases of Diabetic Hepatic Injury

Objective To explore the role of Tanggankang Capsule in decreasing blood sugar, regulating blood lipid and protecting liver for the patient of type 2 diabetes with hepatic injury. Methods 60 cases of type 2 diabetes with hepatic injury, and with TCM syndrome of stagnation of liver-qi and deficiency of spleen, dampness-heat and blood stasis were enrolled in the study. Patients were randomly divided into treatment group (Tanggankang Capsule group, n=30) and control group (Metfofmin and Glucurolactone group, n=30), and were administrated for 8 weeks. Results The total effective rate for the improvement of TCM syndromes was 89.9% in the treatment group and 62.4% in the control group, with significant difference between the two groups (P0.01). On the side of the laboratory indexes of decreasing blood sugar, regulating blood lipids and protecting liver, the treatment group preceded the control group with significant difference (P 0.01 or P0.05). The therapeutic effect of fatty liver, the treatment group (86.7%) preceded the control group (56.7%) with significant difference (P0.05). Conclusion Tanggankang Capsule has remarkable therapeutic effect in improving diabetic hepatic injury.